摘要
艾滋病相关淋巴瘤是常见的艾滋病(AIDS)相关肿瘤之一,高效抗反转录病毒治疗(HAART)被广泛采用后,艾滋病相关淋巴瘤患者的免疫功能增强,对化疗的耐受性提高,预后明显改善。临床研究表明,以HAART与CHOP方案或R-CHOP方案联合治疗弥漫大B细胞淋巴瘤安全有效。HAART治疗后,传统的化疗方案治疗AIDS相关Burkitt淋巴瘤(AIDS-BL)患者存活率仍然很低,而采用Burkitt淋巴瘤特定的短期强烈多药联合方案及LMB-86方案可使AIDS-BL的完全有效率和总生存率明显改善。
AIDS-related lymphoma（ARL） is one of the most common AIDS-defining malignancies.With the widespread use of highly active antiretroviral therapy（HAART）,the immune function of patients with ARL has been improved,the tolerance to cytotoxic chemotherapy is increased,and the prognosis of many patients is hereby significantly improved.Clinical studies suggest that it is safe and effective to use CHOP or R-CHOP,in combination with HAART in patients with AIDS-related diffuse large B-cell lymphoma.However,it is reported that patients with AIDS-related Burkitt subtype,who are treated with conventional chemotherapy regimen,still have a poor survival after the treatment of HAART.However,the complete remission and overall survival were both improved among these patients who received Burkitt-specific short intensive cycles of chemotherapy and LMB-86 regimen.
出处
《医学综述》
2010年第23期3596-3599,共4页
Medical Recapitulate
